Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat [Seeking Alpha]
Immunome, Inc. (IMNM)
Company Research
Source: Seeking Alpha
Varegacestat demonstrated a 56% objective response rate, the highest ever in a randomized desmoid tumor trial, and a marked reduction in tumor volume. I maintain a "Strong Buy" rating, supported by the upcoming NDA filing for varegacestat in Q2 2026 and IM-1021's phase 1 lymphoma data expected in 2026. Company's robust cash position, extended runway into 2027, and differentiated drug profile underpin confidence despite competitive and regulatory risks. SeventyFour/iStock via Getty Images The last time I spoke about Immunome IMNM ) it was with respect to a Seeking Alpha article entitled " Immunome: AL102 And Other Established Protein Targets Could Drive Value ". With respect to More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take
Show less
Read more
Impact Snapshot
Event Time:
IMNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNM alerts
High impacting Immunome, Inc. news events
Weekly update
A roundup of the hottest topics
IMNM
News
- Immunome prices $400M stock offering at $21.50 a share [Seeking Alpha]Seeking Alpha
- Stock Market Today: Russell 2000, Nasdaq Saddle Tech Pullback Ahead of Big Week of Data [Yahoo! Finance]Yahoo! Finance
- Immunome Announces Pricing of Public Offering of Common Stock [Yahoo! Finance]Yahoo! Finance
- Immunome Announces Pricing of Public Offering of Common StockBusiness Wire
- Immunome (NASDAQ:IMNM) had its "buy" rating reaffirmed by analysts at Lake Street Capital.MarketBeat
IMNM
Earnings
- 8/6/25 - Beat
IMNM
Sec Filings
- 12/18/25 - Form 4
- 12/17/25 - Form 8-K
- 12/17/25 - Form 424B5
- IMNM's page on the SEC website